Loading clinical trials...
Loading clinical trials...
A Phase II Study of the Assessment of Response to Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker
Conditions
Interventions
Pembrolizumab
CT Scan
Locations
5
Canada
Kingston Health Sciences Centre
Kingston, Ontario, Canada
London Regional Cancer Program
London, Ontario, Canada
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Odette Cancer Centre
Toronto, Ontario, Canada
Allan Blair Cancer Centre
Regina, Saskatchewan, Canada
Start Date
January 10, 2017
Primary Completion Date
March 22, 2019
Completion Date
September 30, 2019
Last Updated
August 25, 2023
NCT04693377
NCT06500455
NCT06066138
NCT06975293
NCT07112170
NCT07281924
Lead Sponsor
Canadian Cancer Trials Group
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions